Newborn screening for Pompe disease in Japan: report and literature review of mutations in the GAA gene in Japanese and Asian patients

[1]  R. Giugliani,et al.  Newborn Screening for Pompe Disease , 2017, Pediatrics.

[2]  M. Gelb,et al.  Liquid Chromatography-Tandem Mass Spectrometry Assay of Leukocyte Acid α-Glucosidase for Post-Newborn Screening Evaluation of Pompe Disease. , 2017, Clinical chemistry.

[3]  T. Okuyama,et al.  Levels of enzyme activities in six lysosomal storage diseases in Japanese neonates determined by liquid chromatography-tandem mass spectrometry , 2016, Molecular genetics and metabolism reports.

[4]  M. Tarnopolsky,et al.  Pompe Disease: Diagnosis and Management. Evidence-Based Guidelines from a Canadian Expert Panel , 2016, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[5]  Ricardo Villamarín-Salomón,et al.  ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..

[6]  Jana Marie Schwarz,et al.  MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.

[7]  Chih-jou Lai,et al.  A large‐scale nationwide newborn screening program for pompe disease in Taiwan: Towards effective diagnosis and treatment , 2014, American journal of medical genetics. Part A.

[8]  I. Adzhubei,et al.  Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2 , 2013, Current protocols in human genetics.

[9]  I. Nonaka,et al.  Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology , 2012, Neuromuscular Disorders.

[10]  C. Phornphutkul,et al.  The emerging phenotype of long-term survivors with infantile Pompe disease , 2012, Genetics in Medicine.

[11]  F. Endo,et al.  Improved assay for differential diagnosis between Pompe disease and acid α-glucosidase pseudodeficiency on dried blood spots. , 2011, Molecular genetics and metabolism.

[12]  A. Pestronk,et al.  A randomized study of alglucosidase alfa in late-onset Pompe's disease. , 2010, The New England journal of medicine.

[13]  Y. Chien,et al.  Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. , 2010, Molecular genetics and metabolism.

[14]  Akhilesh Pandey,et al.  Mutation@A Glance: An Integrative Web Application for Analysing Mutations from Human Genetic Diseases , 2010, DNA research : an international journal for rapid publication of reports on genes and genomes.

[15]  Y. Chien,et al.  Pompe Disease in Infants: Improving the Prognosis by Newborn Screening and Early Treatment , 2009, Pediatrics.

[16]  J. Clancy,et al.  Early Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease , 2009, Pediatric Research.

[17]  F. Endo,et al.  High frequency of acid alpha-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population. , 2009, Molecular genetics and metabolism.

[18]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.

[19]  R. Wevers,et al.  p.[G576S; E689K]: pathogenic combination or polymorphism in Pompe disease? , 2008, European Journal of Human Genetics.

[20]  W. Hwu,et al.  Identification of eight novel mutations of the acid α-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II , 2008, Journal of Neurology.

[21]  Wei-min Zhang,et al.  [Clinical and molecular genetic study on two patients of the juvenile form of Pompe disease in China]. , 2007, Zhonghua er ke za zhi = Chinese journal of pediatrics.

[22]  B. Byrne,et al.  Recombinant human acid α-glucosidase , 2007, Neurology.

[23]  David M. Rapoport,et al.  Pompe disease diagnosis and management guideline , 2006, Genetics in Medicine.

[24]  W. Hop,et al.  Disease severity in children and adults with Pompe disease related to age and disease duration , 2005, Neurology.

[25]  I. Nonaka,et al.  Frequent mutations in Japanese patients with acid maltase deficiency , 2000, Neuromuscular Disorders.

[26]  M. Kroos,et al.  Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling , 1999, European Journal of Human Genetics.

[27]  C. Tifft,et al.  The African origin of the common mutation in African American patients with glycogen-storage disease type II. , 1998, American journal of human genetics.

[28]  S. Dimauro,et al.  Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation. , 1994, Human molecular genetics.

[29]  S. Brooks,et al.  A de novo 13 nt deletion, a newly identified C647W missense mutation and a deletion of exon 18 in infantile onset glycogen storage disease type II (GSDII). , 1994, Human molecular genetics.

[30]  A. Pellicer,et al.  Isolation of a cDNA for human acid alpha-glucosidase and detection of genetic heterogeneity for mRNA in three alpha-glucosidase-deficient patients. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Byrne,et al.  Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. , 2007, Neurology.

[32]  J. Shieh,et al.  Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: Evidence for a founder effect , 1998, Human mutation.